Reports say Moderna has initiated earliest-stage work on a hantavirus vaccine, driving a sharp market reaction. Coverage tied the move to potential collaboration with the US Army Medical Research Institute of Infectious Diseases and Korea University’s Vaccine Innovation Center, though the company has not disclosed detailed timelines or trial plans. Hantavirus remains without an approved vaccine, and the company’s early activity adds to the infectious-disease pipeline interest that tends to amplify biotech valuation when a plausible near-term platform expansion is mentioned. Investors have historically responded quickly to vaccine program rumors when they imply manufacturing and immunology platform reuse. Still, Moderna’s reported efforts appear in the preclinical/early phase, leaving clinical feasibility and regulatory scope to be defined through later updates.